Patents by Inventor Andreas Holm Mattsson

Andreas Holm Mattsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccines targeting Pseudomonas aeruginosa
    Publication number: 20240076325
    Abstract: Immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins.
    Type: Application
    Filed: June 23, 2023
    Publication date: March 7, 2024
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Peptides derived from and their use in vaccination
    Patent number: 11857615
    Abstract: The present invention relates to proteins derived from Acinetobacter baumanii, nucleic acids encoding the proteins, antibodies specific for the proteins as well as methods of therapy, prophylaxis, and diagnosis that utilise the proteins, nucleic acids, and antibodies.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: January 2, 2024
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 11807669
    Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: November 7, 2023
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Vaccines targeting
    Patent number: 11718648
    Abstract: Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 8, 2023
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Vaccines targeting Neisseria gonorrhoeae
    Publication number: 20230050225
    Abstract: Proteins, protein fragments, nucleic acids and vectors derived from Neisseria gonorrhoeae, as well as to methods of inducing immunity against N. gonorrhoeae. Also disclosed are antibodies binding to the proteins and protein fragments.
    Type: Application
    Filed: January 6, 2021
    Publication date: February 16, 2023
    Inventors: Andreas Holm Mattsson, Christian Skjødt Steenmans
  • Chimeric proteins for inducing immunity towards infection with S. aureus
    Publication number: 20230045507
    Abstract: Disclosed is chimeric polypeptides derived from S. aureus proteins having SEQ ID NOs: 1-9 and 139-146. The chimeric polypeptides are useful as immunogens for providing protective immunity against S. aureus infection. Also disclosed are compositions, methods of treatment and prophylaxis, nucleic acids and vectors comprising the nucleic acids.
    Type: Application
    Filed: July 29, 2022
    Publication date: February 9, 2023
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson, Jens Kringelum
  • Chimeric proteins for inducing immunity towards infection with
    Patent number: 11414464
    Abstract: Disclosed is chimeric polypeptides derived from S. aureus proteins having SEQ ID NOs: 1-9 and 139-146. The chimeric polypeptides are useful as immunogens for providing protective immunity against S. aureus infection. Also disclosed are compositions, methods of treatment and prophylaxis, nucleic acids and vectors comprising the nucleic acids.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: August 16, 2022
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson, Jens Kringelum
  • Vaccines targeting H. influenzae
    Publication number: 20220143168
    Abstract: Immunogenic proteins from nontypable Haemophilus influenzae as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Methods for prophylaxis of infection with nontypable Haemophilus influenzae using the proteins, nucleic acids, vectors or transformed cells.
    Type: Application
    Filed: February 27, 2020
    Publication date: May 12, 2022
    Inventors: Andreas Holm Mattsson, Christian Skjødt Hansen
  • Vaccines targeting M. catharrhalis
    Publication number: 20220111031
    Abstract: Immunogenic proteins from Moraxella catharrhalis as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Methods for prophylaxis of infection with Moraxella catharrhalis using the proteins, nucleic acids, vectors or transformed cells.
    Type: Application
    Filed: October 22, 2019
    Publication date: April 14, 2022
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
    Publication number: 20220073570
    Abstract: Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 10, 2022
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
    Publication number: 20210386847
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Application
    Filed: June 17, 2021
    Publication date: December 16, 2021
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 11052145
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 10946084
    Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: March 16, 2021
    Assignee: Evaxion Biotech ApS
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae
    Publication number: 20210052713
    Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 25, 2021
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 10849968
    Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: December 1, 2020
    Assignee: Evaxion Biotech ApS
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
    Publication number: 20200306356
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Application
    Filed: May 29, 2020
    Publication date: October 1, 2020
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Peptides derived from Acinetobacter Baumannii and their use in vaccination
    Publication number: 20200268866
    Abstract: The present invention relates to proteins derived from Acinetobacter Baumanii, nucleic acids encoding the proteins, antibodies specific for the proteins as well as methods of therapy, prophylaxis, and diagnosis that utilise the proteins, nucleic acids, and antibodies.
    Type: Application
    Filed: March 4, 2020
    Publication date: August 27, 2020
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 10675340
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 9, 2020
    Assignee: Evaxion Biotech ApS
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
    Publication number: 20200031878
    Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 30, 2020
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae
    Publication number: 20200023049
    Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 23, 2020
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson